10 results on '"Zuleger, Cindy L"'
Search Results
2. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.
- Author
-
Magee, Kara, Marsh, Ian R., Turek, Michelle M., Grudzinski, Joseph, Aluicio-Sarduy, Eduardo, Engle, Jonathan W., Kurzman, Ilene D., Zuleger, Cindy L., Oseid, Elizabeth A., Jaskowiak, Christine, Albertini, Mark R., Esbona, Karla, Bednarz, Bryan, Sondel, Paul M., Weichert, Jamey P., Morris, Zachary S., Hernandez, Reinier, and Vail, David M.
- Subjects
RADIATION dosimetry ,DOSIMETERS ,EXTERNAL beam radiotherapy ,POSITRON emission tomography ,GENE expression profiling ,CANCER vaccines ,VACCINATION ,DOGS - Abstract
Rationale: Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the safety and feasibility of this approach in a relevant translational companion dog model (n = 17 dogs) with advanced cancer. Methods: The three component of the combination immuno-radiotherapy approach were employed either separately or in combination in companion dogs with advanced stage cancer. In situ vaccination was achieved through the administration of hypofractionated external beam radiotherapy and intratumoral hu14.18-IL2 fusion immunocytokine injections to the index tumor. In situ vaccination was subsequently combined with targeted radionuclide therapy using a theranostic pairing of IV
86 Y-NM600 (for PET imaging and subject-specific dosimetry) and IV90 Y-NM600 (therapeutic radionuclide) prescribed to deliver an immunomodulatory 2 Gy dose to all metastatic sites in companion dogs with metastatic melanoma or osteosarcoma. In a subset of dogs, immunologic parameters preliminarily assessed. Results: The components of the immuno-radiotherapy combination were well tolerated either alone or in combination, resulting in only transient low grade (1 or 2) adverse events with no dose-limiting events observed. In subject-specific dosimetry analyses, we observed86 Y-NM600 tumor:bone marrow absorbed-dose differential uptakes ≥2 in 4 of 5 dogs receiving the combination, which allowed subsequent safe delivery of at least 2 Gy90 Y-NM600 TRT to tumors. NanoString gene expression profiling and immunohistochemistry from pre- and post-treatment biopsy specimens provide evidence of tumor microenvironment immunomodulation by90 Y-NM600 TRT. Conclusions: The combination of external beam radiotherapy, intratumoral immunocytokine, and targeted radionuclide immuno-radiotherapy known to have activity against syngeneic melanoma in murine models is feasible and well tolerated in companion dogs with advanced stage, spontaneously arising melanoma or osteosarcoma and has immunomodulatory potential. Further studies evaluating the dose-dependent immunomodulatory effects of this immuno-radiotherapy combination are currently ongoing. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients.
- Author
-
Zuleger, Cindy L., Newton, Michael A., Ma, Xiuyu, Ong, Irene M., Pei, Qinglin, and Albertini, Mark R.
- Published
- 2020
- Full Text
- View/download PDF
4. NK cells propagate T cell immunity following in situ tumor vaccination.
- Author
-
Jin, Won Jong, Jagodinsky, Justin C., Vera, Jessica M., Clark, Paul A., Zuleger, Cindy L., Erbe, Amy K., Ong, Irene M., Le, Trang, Tetreault, Kaitlin, Berg, Tracy, Rakhmilevich, Alexander L., Kim, KyungMann, Newton, Michael A., Albertini, Mark R., Sondel, Paul M., and Morris, Zachary S.
- Abstract
We report an in situ vaccination, adaptable to nearly any type of cancer, that combines radiotherapy targeting one tumor and intratumoral injection of this site with tumor-specific antibody and interleukin-2 (IL-2; 3xTx). In a phase I clinical trial, administration of 3xTx (with an immunocytokine fusion of tumor-specific antibody and IL-2, hu14.18-IL2) to subjects with metastatic melanoma increases peripheral CD8
+ T cell effector polyfunctionality. This suggests the potential for 3xTx to promote antitumor immunity against metastatic tumors. In poorly immunogenic syngeneic murine melanoma or head and neck carcinoma models, 3xTx stimulates CD8+ T cell-mediated antitumor responses at targeted and non-targeted tumors. During 3xTx treatment, natural killer (NK) cells promote CTLA4+ regulatory T cell (T reg) apoptosis in non-targeted tumors. This is dependent on NK cell expression of CD86, which is upregulated downstream of KLRK1. NK cell depletion increases T reg infiltration, diminishing CD8+ T cell-dependent antitumor response. These findings demonstrate that NK cells sustain and propagate CD8+ T cell immunity following 3xTx. [Display omitted] • In situ vaccine effect of radiation, antibody, and IL-2 injection (3xTx) • 3xTx elicits enhanced infiltration of T cells and NK cells in non-targeted tumors • NK cell depletion increases regulatory T cell infiltration in non-targeted tumors • NK cells antagonize CTLA4+ T reg and elicit CD8+ T cell immunity Jin et al. developed an in situ vaccination approach that combines radiation and intratumoral injection of a tumor-specific antibody and IL-2 (3xTx). This targeted 3xTx regimen elicits CD8+ T cell immunity supported by NK cell-mediated regulatory T cell antagonism in non-targeted tumors. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
- Author
-
Albertini, Mark R., Yang, Richard K., Ranheim, Erik A., Hank, Jacquelyn A., Zuleger, Cindy L., Weber, Sharon, Neuman, Heather, Hartig, Greg, Weigel, Tracey, Mahvi, David, Henry, Mary Beth, Quale, Renae, McFarland, Thomas, Gan, Jacek, Carmichael, Lakeesha, Kim, KyungMann, Loibner, Hans, Gillies, Stephen D., and Sondel, Paul M.
- Subjects
IPILIMUMAB ,MELANOMA ,IMMUNOTHERAPY ,CANCER treatment ,MELANOMA treatment - Abstract
Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m
2 /day. Preclinical data in IC-treated tumor-bearing mice with low tumor burden documented striking antitumor effects. Patients with completely resectable recurrent stage III or stage IV melanoma were scheduled to receive 3 courses of IC at 6 mg/m2 /day i.v. on days 1, 2 and 3 of each 28-day course. Patients were randomized to complete surgical resection either following neoadjuvant (Group A) or prior to adjuvant (Group B) IC course 1. Primary objectives were to: (1) evaluate histological evidence of anti-tumor activity and (2) evaluate recurrence-free survival (RFS) and OS. Twenty melanoma patients were randomized to Group A (11 patients) or B (9 patients). Two Group B patients did not receive IC due to persistent disease following surgery. Six of 18 IC-treated patients remained free of recurrence, with a median RFS of 5.7 months (95% confidence interval (CI) 1.8-not reached). The 24-month RFS rate was 38.9% (95% CI 17.5-60.0%). The median follow-up of surviving patients was 50.0 months (range: 31.8-70.4). The 24-month OS rate was 65.0% (95% CI 40.3-81.5%). Toxicities were similar to those previously reported. Exploratory tumor-infiltrating lymphocyte (TIL) analyses suggest prognostic value of TILs from Group A patients. Prolonged tumor-free survival was seen in some melanoma patients at high risk for recurrence who were treated with IC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
6. Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.
- Author
-
Zuleger, Cindy L., Kang, Chulhi, Ranheim, Erik A., Kurzman, Ilene D., Macklin, Michael D., Newton, Michael A., Wolchok, Jedd D., Vail, David M., Eriksson, Elof, and Albertini, Mark R.
- Subjects
MELANOMA ,PHENOL oxidase ,DNA vaccines ,ENZYME-linked immunosorbent assay ,CANCER immunotherapy - Abstract
Spontaneous canine malignant melanoma provides an excellent pre-clinical model to study DNA vaccines for melanoma immunotherapy. A USDA-approved xenogeneic human tyrosinase (hu TYR) plasmid DNA vaccine delivered intramuscularly induces detectable immune responses and has clinical activity in some dogs with melanoma. The objective of this pilot study was to evaluate the feasibility, safety and immunogenicity of hu TYR plasmid DNA administered to the skin via microseeding in dogs with spontaneous melanoma. DNA microseeding utilizes a modified tattooing device as an alternate and potentially more potent delivery method for DNA immunization. DNA was delivered to shaved inner thigh skin of six companion dogs with melanoma approximately every 14 days for a planned total of four vaccination time points. An anti-hu TYR ELISA was used to test pre- and post-treatment sera. Biopsies of treated skin were obtained for detection of hu TYR transgene expression. DNA microseeding was well tolerated with no significant toxicity detected beyond local site irritation, and there were no signs of autoimmunity. hu TYR-expressing cells were observed in biopsies of hu TYR DNA microseeding sites. Increased humoral anti-hu TYR antibodies were seen in two of five evaluable dogs following microseeding compared to baseline. DNA microseeding is well tolerated in companion dogs with melanoma. Further investigation is needed to determine if combining DNA microseeding with other immunotherapy regimens potentiates this delivery platform for cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. A conditional predictive p-value to compare a multinomial with an overdispersed multinomial in the analysis of T-cell populations.
- Author
-
Pei, Qinglin, Zuleger, Cindy L., Macklin, Michael D., Albertini, Mark R., and Newton, Michael A.
- Subjects
T cells ,CELL populations ,IMMUNOLOGY ,MOLECULAR biology ,CONSTRAINT satisfaction ,CYTOLOGY ,COMPARATIVE studies ,PREDICTION models - Abstract
Immunological experiments that record primary molecular sequences of T-cell receptors produce moderate to high-dimensional categorical data, some of which may be subject to extra-multinomial variation caused by technical constraints of cell-based assays. Motivated by such experiments in melanoma research, we develop a statistical procedure for testing the equality of two discrete populations, where one population delivers multinomial data and the other is subject to a specific form of overdispersion. The procedure computes a conditional-predictive p-value by splitting the data set into two, obtaining a predictive distribution for one piece given the other, and using the observed predictive ordinate to generate a p-value. The procedure has a simple interpretation, requires fewer modeling assumptions than would be required of a fully Bayesian analysis, and has reasonable operating characteristics as evidenced empirically and by asymptotic analysis. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
8. Clonal Expansions of 6-Thioguanine Resistant T Lymphocytes in the Blood and Tumor of Melanoma Patients.
- Author
-
Albertini, Mark R., Macklin, Michael D., Zuleger, Cindy L., Newton, Michael A., Judice, Stephen A., and Albertini, Richard J.
- Subjects
T cells ,LYMPHOCYTES ,TUMORS ,MELANOMA ,PATIENTS ,CANCER treatment ,IMMUNE response ,BLOOD ,LEUCOCYTES - Abstract
The article discusses the study that examines the blood and tumor of melanoma patients for clonal expansions of 6-Thioguanine resistant T Lymphocytes. It investigates specific lymphocytes that mediate tumor immune responses required for elucidating the mechanisms underlying these responses and facilitating treatment interventions in human with cancer. It indicates that the mutant T-cell fractions from melanoma patients are improved for proliferating T-cells that infiltrate the tumor, thus, making them potential candidates for investigations of protective immunological responses.
- Published
- 2008
- Full Text
- View/download PDF
9. Immune responses to hepatitis B surface antigen following epidermal powder immunization.
- Author
-
Osorio, Jorge E, Zuleger, Cindy L, Burger, Melissa, Chu, Qili, Payne, Lendon G, and Chen, Dexiang
- Subjects
IMMUNIZATION ,HEPATITIS B ,LANGERHANS cells - Abstract
Summary Langerhans cells in the epidermis of skin are potent antigen-presenting cells that trigger the immune system to respond to invading microorganisms. We have previously shown that epidermal powder immunization with a powdered inactivated influenza virus vaccine, by targeting the Langerhans cell-rich epidermis, was more efficacious than deeper tissue injection using a needle and syringe. We now report enhanced humoral and cellular immune responses to recombinant hepatitis B surface antigen following epidermal powder immunization. We observed that epidermal powder immunization with unadjuvanted hepatitis B surface antigen elicited an antibody titre equivalent to that induced by the alum-adjuvanted vaccine delivered by intramuscular injection, suggesting that epidermal powder immunization can overcome the need for adjuvantation. We demonstrated that synthetic CpG oligonucleotides (CpG DNA) could be coformulated with hepatitis B surface antigen and delivered by epidermal powder immunization to further augment the antibody response and modulate T helper cell activities. Epidermal powder immunization of hepatitis B surface antigen formulated with CpG DNA formulations resulted in 1.5-2.0 logs higher IgG antibody titres than alum-adjuvanted commercial vaccines administered by intramuscular injection. Formulation of hepatitis B surface antigen with CpG DNA elicited an augmented IgG2a antibody response and increased frequency of IFN-γ secreting cells. In addition, CpG DNA was found to activate epidermal Langerhans cells and stimulate the production of TNF-α and IL-12 cytokines by epidermal cells, explaining its strong adjuvant activity following epidermal powder immunization. These results show that epidermal powder immunization is a safe and effective method to deliver hepatitis B surface antigen and the addition of new adjuvants, such as CpG DNA, may further enhance the efficacy of this vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
10. OMIP-008: Measurement of Th1 and Th2 cytokine polyfunctionality of human T cells.
- Author
-
Zuleger, Cindy L. and Albertini, Mark R.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.